Atherosclerosis

PHILADELPHIA — Despite there being few options to directly lower lipoprotein(a) as of yet, measurement is none the less important to identify those who would benefit from improved risk factor control, a speaker reported.

The nature of the relationship between discrimination, smoking and features of CVD is complex and varies by race and sex, according to a moderated mediation analysis published in the Journal of the American Heart Association.

Cleerly has received FDA breakthrough device designation for its coronary artery disease staging system, which was also accepted into the FDA’s Total Product Life Cycle Advisory Program Pilot, according to a company press release.

Among patients with asymptomatic carotid artery disease who had carotid endarterectomy, those whose atheromas contained microplastics and/or nanoplastics had worse outcomes than those whose atheromas did not, researchers reported.

Among patients with stable chest pain referred for invasive coronary angiography, a low coronary artery calcium score was associated with low risk for heart attack and stroke, researchers reported in Radiology.

Older adults with a coronary artery calcium score of 0 had more favorable aging indices, including normal cognitive function, vascular function and better hearing, compared with those with CAC scores of 1,000 or greater, data show.

Adults who report experiencing financial strain have lower odds of having average and optimal CV health measures, suggesting psychosocial stress can impact CVD risk, researchers reported.

Researchers reported that a universal risk prediction model incorporating traditional risk factors and cardiac biomarkers accurately estimated risk for adults both with and without baseline atherosclerotic CVD.

Elevated lipid levels were associated with worsening structural and functional cardiac damage in adolescents and young adults, though in the case of LDL, the relationship was partially mediated by elevated BP and fat mass, data show.

Patients with type 2 diabetes and chronic kidney disease receiving empagliflozin were less likely to experience a decline in eGFR compared with patients taking placebo, results from a newly published study show.